-
Illuminating the Multifaceted Role of Acetylation: Bridging Chemistry and Biology Introduction:(Post)
Acetylation, a chemical process characterized by the addition of an acetyl functional group to a molecule, stands as a cornerstone in both biochemical and biological landscapes. Its significanc
Antibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated Antigens(Post)Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes
Waardenburg Syndrome and Klein-Waardenburg Syndrome(Post)Waardenburg Syndrome: A Rare Genetic Disorder Affecting Pigmentation, Hearing, and More Waardenburg Syndrome (WS) is a fascinating and rare genetic disorder that impacts various aspe
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond(Post)What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
QuickStep ELISA Kits(Page)QuickStep ELISA Kits | 90-Minute 1-Wash Assays | Assay Genie
Fc Receptors Explained: ADCC, ADCP, CDC and the CD32B Brake(Post)An antibody's variable domains decide what it binds. Its Fc decides what happens next — and that is not a detail of formulation, it is half the mechanism. Which Fcγ receptor the constant region engag
COVID-19 Antibody Testing(Post)COVID-19 Antibody Testing Antibody Production in COVID-19 COVID-19, the novel coronavirus disease
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Ozuriftamab: A Closer Look at This Anti-CD47 Antibody in Cancer Immunotherapy(Post)What You Need to Know About OzuriftamabWhat is Ozuriftamab?Ozuriftamab is an investigational monoclonal antibody targeting CD47, designed to enhance immune-mediated clearance of cancer c
세포 용해를위한 소니케이션(초음파 처리 분해) 프로토콜 (Page) Combien coûte réellement un anticorps de recherche ?(Post)Combien coûte réellement un anticorps de recherche ? Prévoyez un budget de 130 à 2 500 dollars par anticorps selon le format et l’application visée, mais ce chiffre ne raconte qu’une partie de l’hist
Avant le premier pipetage : plan expérimental ELISA, modèles copiables(Post)Un plan expérimental ELISA fiable repose sur six éléments non négociables: des contrôles complets (blanc, négatif, positif, matrice), des étalons pour la courbe de calibration, une série de diluti
Unlocking the Next Wave of Cancer Treatment: The Promise and Progress of CAR-T Cell Therapy(Post)Imagine a living drug, engineered from a patient's own immune system, that can hunt down and destroy cancer cells with remarkable precision. This isn't science fiction; it's the reality of Chimeric An
Bone Morphogenetic Proteins (BMP) – Review(Post)Bone Morphogenetic Proteins (BMP) were first discovered in the 1960s by Dr.Marshall Urist, an orthopaedic surgeon at UCLA (Urist 1965). BMPs are classically associated with their roles in limb
Begelomab: Mechanism of Action, Clinical Applications & Biosimilars(Post)Quick Facts About BegelomabWhat is Begelomab?Begelomab is a monoclonal antibody that targets CD26, a key molecule involved in immune regulation. It has been studied for its potential app
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m
Binding Is the Easy Part(Post)An antibody–drug conjugate is not a targeted drug. It is a delivery problem with an antibody bolted to the front of it. Binding is the easy part, and it is almost never the part that fails. What deci
ELISA மதிப்பீடு, கொள்கை, நெறிமுறைகள், முறைகள் மற்றும் கருவிகள்(Page) Unlocking the Fortress: CAR-T Cell Therapy's Next Frontier in Solid Tumors(Post)For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form